The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.
bicalutamide results in decreased expression of ADRB2 mRNA; bicalutamide results in decreased expression of ADRB2 protein bicalutamide inhibits the reaction [Triiodothyronine results in increased expression of ADRB2 protein]
AR gene mutant form results in decreased susceptibility to bicalutamide; AR protein alternative form results in decreased susceptibility to bicalutamide bicalutamide affects the localization of AR protein [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [bicalutamide binds to and results in decreased activity of AR protein] inhibits the reaction [Dehydroepiandrosterone results in decreased expression of CYP1A2 mRNA]; [bicalutamide co-treated with Testosterone] affects the expression of and results in decreased activity of AR protein; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of and affects the localization of AR protein alternative form; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR mRNA; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR mRNA alternative form; [bicalutamide results in decreased susceptibility to bicalutamide] which results in increased expression of AR protein; [Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to PHB1 protein]; [Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to SMARCA4 protein]; [Goserelin co-treated with bicalutamide] results in decreased expression of AR protein; [Goserelin co-treated with Dutasteride co-treated with bicalutamide co-treated with Ketoconazole] results in decreased expression of AR protein; [Goserelin co-treated with Dutasteride co-treated with bicalutamide] results in decreased expression of AR protein; AR protein promotes the reaction [bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]]; bicalutamide affects the reaction [beta-hexachlorocyclohexane affects the expression of AR protein]; bicalutamide affects the reaction [Testosterone affects the expression of AR protein]; bicalutamide binds to and affects the localization of and affects the activity of AR protein; bicalutamide binds to and results in decreased activity of AR protein; bicalutamide binds to and results in increased activity of AR protein mutant form; bicalutamide inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; bicalutamide inhibits the reaction [[Dihydrotestosterone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [[Metribolone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [alpha-naphthoflavone inhibits the reaction [Particulate Matter analog inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]]]; bicalutamide inhibits the reaction [alpha-naphthoflavone inhibits the reaction [Vehicle Emissions analog inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]]]; bicalutamide inhibits the reaction [AR protein alternative form binds to KLK3 promoter]; bicalutamide inhibits the reaction [AR protein alternative form promotes the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; bicalutamide inhibits the reaction [AR protein binds to KLK3 promoter]; bicalutamide inhibits the reaction [AR protein binds to NCOA1 protein]; bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; bicalutamide inhibits the reaction [Cadmium Chloride results in decreased expression of AR mRNA]; bicalutamide inhibits the reaction [Cadmium Chloride results in decreased expression of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone affects the localization of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone binds to AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of AR mRNA]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of and results in increased phosphorylation of AR protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; bicalutamide inhibits the reaction [Estradiol results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Estradiol results in increased activity of AR protein]; bicalutamide inhibits the reaction [Fludrocortisone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Flutamide results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [laxogenin analog results in increased activity of AR protein]; bicalutamide inhibits the reaction [Metribolone results in increased activity of AR protein mutant form]; bicalutamide inhibits the reaction [Metribolone results in increased activity of AR protein]; bicalutamide inhibits the reaction [Metribolone results in increased folding of and results in increased stability of AR protein]; bicalutamide inhibits the reaction [OSM protein results in increased activity of AR protein]; bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein]; bicalutamide inhibits the reaction [Testosterone results in increased activity of AR protein]; bicalutamide promotes the reaction [AR protein binds to KLK3 promoter]; bicalutamide promotes the reaction [AR protein binds to NCOR2 protein]; bicalutamide promotes the reaction [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein]; methoxyacetic acid inhibits the reaction [bicalutamide inhibits the reaction [Testosterone results in increased activity of AR protein]]; mibolerone inhibits the reaction [bicalutamide results in increased expression of AR protein]; Resveratrol promotes the reaction [bicalutamide results in decreased activity of AR protein] AR protein affects the susceptibility to bicalutamide [bicalutamide binds to AR protein] which binds to KLK3 promoter; bicalutamide binds to AR protein bicalutamide results in decreased expression of AR; bicalutamide results in decreased expression of AR mRNA bicalutamide results in increased expression of AR; bicalutamide results in increased expression of AR protein bicalutamide results in increased localization of and results in increased activity of AR protein bicalutamide binds to and results in decreased activity of AR protein; bicalutamide inhibits the reaction [[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]] bicalutamide results in decreased expression of AR protein
bicalutamide results in decreased expression of BAX [bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of BAX protein; [Niclosamide co-treated with bicalutamide] results in increased expression of BAX protein; bicalutamide inhibits the reaction [Niclosamide results in decreased expression of BAX protein] bicalutamide results in increased expression of BAX protein
bicalutamide results in increased expression of BCL2 bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2 protein]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2 protein]
bicalutamide results in decreased expression of BCL2L1 protein bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2L1 protein]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2L1 protein]
[bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of CASP3 protein; bicalutamide results in increased cleavage of and results in increased activity of CASP3 protein
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]
bicalutamide results in increased expression of CDKN1A; bicalutamide results in increased expression of CDKN1A mRNA; bicalutamide results in increased expression of CDKN1A protein [bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of CDKN1A protein
bicalutamide inhibits the reaction [Metribolone results in increased expression of CLU mRNA]; bicalutamide inhibits the reaction [Metribolone results in increased expression of CLU protein]
bicalutamide results in decreased expression of CUBN protein bicalutamide promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of CUBN protein]
bicalutamide inhibits the reaction [Androstenedione results in increased expression of CYP11A1 protein]; bicalutamide inhibits the reaction [Testosterone results in increased expression of CYP11A1 protein]
bicalutamide inhibits the reaction [Androstenedione results in increased expression of CYP19A1 protein]; bicalutamide inhibits the reaction [Testosterone results in increased expression of CYP19A1 protein]
[bicalutamide binds to and results in decreased activity of AR protein] inhibits the reaction [Dehydroepiandrosterone results in decreased expression of CYP1A2 mRNA]; bicalutamide inhibits the reaction [Dehydroepiandrosterone results in increased degradation of CYP1A2 mRNA]
bicalutamide inhibits the reaction [[Testosterone binds to AR protein] inhibits the reaction [Dexamethasone results in increased expression of DDIT4 mRNA]]
bicalutamide results in decreased expression of DRD4 mRNA FSHB protein inhibits the reaction [bicalutamide results in decreased expression of DRD4 protein]
bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; bicalutamide inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]
bicalutamide results in decreased expression of EPPIN mRNA FSHB protein inhibits the reaction [bicalutamide results in decreased expression of EPPIN protein]
bicalutamide inhibits the reaction [Metribolone results in increased expression of EZR mRNA]; bicalutamide inhibits the reaction [Metribolone results in increased phosphorylation of EZR protein]
bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of FOS mRNA]; bicalutamide inhibits the reaction [FOS protein results in increased expression of EGF mRNA]
FSHB protein inhibits the reaction [bicalutamide results in decreased expression of DRD4 protein]; FSHB protein inhibits the reaction [bicalutamide results in decreased expression of EPPIN protein]; FSHB protein inhibits the reaction [bicalutamide results in decreased expression of GPD1 protein]; FSHB protein inhibits the reaction [bicalutamide results in decreased expression of RHOX5 protein]
bicalutamide results in decreased expression of GPD1 mRNA FSHB protein inhibits the reaction [bicalutamide results in decreased expression of GPD1 protein]
bicalutamide results in increased expression of HIF1A protein bicalutamide promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of HIF1A protein]
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]
[bicalutamide co-treated with Tamoxifen] results in decreased expression of IGF1 protein; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of IGF1 mRNA] bicalutamide results in increased expression of IGF1 mRNA; bicalutamide results in increased expression of IGF1 protein
bicalutamide promotes the reaction [Dihydrotestosterone results in increased expression of IGFBP2 mRNA] bicalutamide results in increased expression of IGFBP2 mRNA
[bicalutamide co-treated with Tamoxifen] results in increased expression of IGFBP3 protein bicalutamide results in decreased expression of IGFBP3 mRNA bicalutamide results in decreased secretion of IGFBP3 protein bicalutamide results in increased expression of IGFBP3 mRNA bicalutamide results in increased expression of IGFBP3 protein
[IL6 protein results in increased expression of NCOA2 protein] which results in decreased susceptibility to bicalutamide; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [BCG Vaccine results in increased expression of IL6 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]]; bicalutamide inhibits the reaction [IL6 protein results in increased expression of KLK3 mRNA]
bicalutamide results in decreased secretion of KLK3 protein [Goserelin co-treated with bicalutamide] results in decreased expression of KLK3 protein; [Goserelin co-treated with Dutasteride co-treated with bicalutamide co-treated with Ketoconazole] results in decreased expression of KLK3 protein; [Goserelin co-treated with Dutasteride co-treated with bicalutamide] results in decreased expression of KLK3 protein; [Niclosamide co-treated with bicalutamide] results in decreased expression of KLK3 mRNA; AR protein promotes the reaction [bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]]; bicalutamide inhibits the reaction [[Dihydrotestosterone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [[Metribolone binds to and results in increased activity of AR protein] which results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of KLK3 mRNA]; bicalutamide inhibits the reaction [AR protein alternative form binds to KLK3 promoter]; bicalutamide inhibits the reaction [AR protein alternative form promotes the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; bicalutamide inhibits the reaction [AR protein binds to KLK3 promoter]; bicalutamide inhibits the reaction [beta-hexachlorocyclohexane results in increased expression of KLK3 mRNA]; bicalutamide inhibits the reaction [Butyrates results in increased expression of KLK3 mRNA]; bicalutamide inhibits the reaction [Dehydroepiandrosterone results in increased expression of KLK3 mRNA]; bicalutamide inhibits the reaction [Dehydroepiandrosterone results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased secretion of KLK3 protein]; bicalutamide inhibits the reaction [Estradiol results in increased expression of KLK3 mRNA]; bicalutamide inhibits the reaction [Estradiol results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [IL6 protein results in increased expression of KLK3 mRNA]; bicalutamide inhibits the reaction [Sirolimus results in increased expression of KLK3 protein]; bicalutamide inhibits the reaction [Testosterone results in increased expression of KLK3 mRNA]; bicalutamide inhibits the reaction [Testosterone results in increased expression of KLK3 protein]; bicalutamide promotes the reaction [AR protein binds to KLK3 promoter]; bicalutamide promotes the reaction [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [PA2G4 protein binds to KLK3 promoter]; bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]; bicalutamide promotes the reaction [PTEN protein results in decreased expression of KLK3 mRNA]; bicalutamide promotes the reaction [SMARCA4 protein binds to KLK3 promoter]; mibolerone inhibits the reaction [bicalutamide results in increased expression of KLK3 protein]; PHB1 protein promotes the reaction [bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; PHB1 protein promotes the reaction [bicalutamide promotes the reaction [SMARCA4 protein binds to KLK3 promoter]] [bicalutamide binds to AR protein] which binds to KLK3 promoter bicalutamide results in decreased expression of KLK3 mRNA; bicalutamide results in decreased expression of KLK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; bicalutamide results in increased phosphorylation of and results in increased activity of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAPK3 protein]; bicalutamide results in increased phosphorylation of and results in increased activity of MAPK3 protein
bicalutamide inhibits the reaction [Dehydroepiandrosterone results in increased expression of MIR21 mRNA]; bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA]; bicalutamide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA]; bicalutamide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA]
[Niclosamide co-treated with bicalutamide] results in decreased expression of MYC mRNA; [Niclosamide co-treated with bicalutamide] results in decreased expression of MYC protein; bicalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of MYC mRNA]; Niclosamide inhibits the reaction [bicalutamide results in increased expression of MYC protein] bicalutamide results in decreased expression of MYC mRNA
[Niclosamide co-treated with bicalutamide] results in decreased expression of NKX3-1 mRNA; bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA]; bicalutamide inhibits the reaction [Cadmium Chloride results in increased expression of NKX3-1 mRNA]; bicalutamide inhibits the reaction [Metribolone results in increased expression of NKX3-1 mRNA] bicalutamide results in decreased expression of NKX3-1 mRNA
[Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to PHB1 protein]; AR protein promotes the reaction [bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [PHB1 protein binds to KLK3 promoter]; PHB1 protein promotes the reaction [bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; PHB1 protein promotes the reaction [bicalutamide promotes the reaction [SMARCA4 protein binds to KLK3 promoter]]
bicalutamide results in decreased expression of PIP mRNA bicalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of PIP mRNA]
bicalutamide promotes the reaction [PTEN protein results in decreased expression of KLK3 mRNA] bicalutamide results in increased activity of PTEN protein
bicalutamide promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of SLC2A1 protein] bicalutamide results in decreased expression of SLC2A1 protein bicalutamide results in increased expression of SLC2A1 protein
[Dihydrotestosterone co-treated with bicalutamide] promotes the reaction [AR protein binds to SMARCA4 protein]; bicalutamide promotes the reaction [SMARCA4 protein binds to KLK3 promoter]; PHB1 protein promotes the reaction [bicalutamide promotes the reaction [SMARCA4 protein binds to KLK3 promoter]]
bicalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of TMSB4X mRNA] bicalutamide results in increased expression of TMSB4X mRNA
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]
bicalutamide results in increased expression of TP53 protein bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein]
bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 mRNA]]; bicalutamide inhibits the reaction [Dihydrotestosterone inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]
browse the term
